Compare ERO & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | PBH |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2021 | 2004 |
| Metric | ERO | PBH |
|---|---|---|
| Price | $40.79 | $51.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $36.50 | ★ $75.33 |
| AVG Volume (30 Days) | ★ 1.4M | 519.2K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $975,777,000.00 |
| Revenue This Year | $51.94 | N/A |
| Revenue Next Year | $2.43 | $4.31 |
| P/E Ratio | ★ $22.61 | $85.28 |
| Revenue Growth | N/A | ★ 36.77 |
| 52 Week Low | $13.91 | $42.62 |
| 52 Week High | $39.88 | $71.07 |
| Indicator | ERO | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 67.48 | 53.36 |
| Support Level | $23.15 | $50.49 |
| Resistance Level | $39.80 | $55.99 |
| Average True Range (ATR) | 1.67 | 1.67 |
| MACD | 0.42 | -0.16 |
| Stochastic Oscillator | 83.79 | 35.46 |
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.